Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiotropium bromide.

P J Barnes1

  • 1Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse St, London SW3 6LY, UK. p.j.barnes@ic.ac.uk

Expert Opinion on Investigational Drugs
|April 3, 2001
PubMed
Summary
This summary is machine-generated.

Tiotropium bromide offers a long-lasting bronchodilator effect for chronic obstructive pulmonary disease (COPD) patients. This new anticholinergic drug improves lung function and reduces symptoms more effectively than ipratropium bromide.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid resistance in asthma.

American journal of respiratory and critical care medicine·1995
Same author

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

The Journal of experimental medicine·1995
Same author

Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

Molecular pharmacology·1995
Same author

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages.

The American journal of physiology·1995
Same author

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction.

Thorax·1995
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Tiotropium bromide is a novel, long-acting anticholinergic bronchodilator.
  • It is a quaternary ammonium derivative with high affinity and slow dissociation from M(1) and M(3) muscarinic receptors.

Purpose of the Study:

  • To evaluate the bronchodilator and bronchoprotective effects of tiotropium bromide.
  • To compare the efficacy of tiotropium bromide with ipratropium bromide in patients with chronic obstructive pulmonary disease (COPD).

Main Methods:

  • Pharmacology studies in animal and human airways.
  • Phase II studies assessing single inhaled doses in asthmatic and COPD patients.
  • Phase III studies evaluating once-daily inhaled tiotropium in COPD patients.

Related Experiment Videos

Main Results:

  • Single inhaled doses of tiotropium bromide demonstrated bronchodilator and bronchoprotective effects lasting over 24 hours in Phase II studies.
  • Once-daily inhaled tiotropium showed greater improvement in lung function and symptom reduction in COPD patients compared to four-times-daily ipratropium bromide in Phase III studies.
  • The drug was well-tolerated, with dry mouth being the most common side effect (approx. 10%).

Conclusions:

  • Tiotropium bromide is an effective long-acting bronchodilator for COPD management.
  • Its efficacy and prolonged action suggest it may become a preferred treatment for COPD.
  • Anticholinergics are established as a primary choice for bronchodilation in COPD.